서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 57

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-07
Docetaxel+5-fluorouracil plus cisplatin 3-day combination chemotherapy as a first-line treatment in patient with unresectable gastric cancer
DOI
2007-04
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
view fileDOI
2008-03
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer
DOI
2010-06
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
DOI
2012-04
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
DOI
2012-05
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
DOI
2012-08
Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy
DOI
2012-08
EGFR mutations as a predictive marker of cytotoxic chemotherapy
DOI
2013-03
Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report

Choi, Ik Joon; Kim, Dong-Wan; Kim, Dong-Young; Lee, Chul Hee; Rhee, Chae-Seo

Acta Oto-Laryngologica, Vol.133 No.3, pp.291-296

DOI
2013-04
Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases
DOI
2013-05
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
DOI
2013-06
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
DOI
2013-07
Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy
DOI
2013-07
Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer
DOI
2014-06
Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery

Lee, Jae-Young; Kim, Jung Sun; Cho, Hyun-Jong; Kim, Dae-Duk

International journal of nanomedicine, Vol.9 No.1, pp.2803-2813

DOI
2014-07
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
DOI
2014-11
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer

Baselga, Jose; Cortes, Javier; Im, Seock-Ah; Clark, Emma; Ross, Graham; Kiermaier, Astrid; Swain, Sandra M.

Journal of Clinical Oncology, Vol.32 No.33, pp.3753-3761

DOI
2015-03
Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer
DOI
2016-02
Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience
DOI
2016-03
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
DOI
2016-04
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
DOI
2016-06
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
DOI
2016-07
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
DOI
2016-12
Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
DOI
2017-01
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
DOI
2017-06
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
DOI
2017-09
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
DOI
2017-11
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study
DOI
2018-02
Phase I pharmacokinetic study of nivolumab in Korean patients with advanced solid tumors
DOI
2018-03
Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE
DOI
2018-04
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
DOI
2018-05
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

Pivot, Xavier; Im, Seock Ah; Guo, Matthew; Marme, Frederik

Breast Cancer, Vol.25 No.3, pp.370-374

DOI
2018-06
Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer

Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Thoracic Cancer, Vol.9 No.6, pp.736-744

view fileDOI
2018-08
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-06
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
DOI
2019-07
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer
view fileDOI
2019-07
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
DOI
1 2